Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
IBI-389
i
Other names:
IBI-389, IBI389, IBI 389
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Innovent Biologics
Drug class:
CD3 agonist, CLDN18.2 inhibitor
Related drugs:
‹
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
VIR-5818 (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
MK-4002 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AB011 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
blinatumomab (52)
epcoritamab-bysp (11)
elranatamab-bcmm (8)
tebentafusp-tebn (7)
MGD006 (6)
BI 764532 (5)
tarlatamab-dlle (4)
SAR442257 (4)
AZD5863 (3)
CTIM-76 (3)
EX103 (3)
JNJ-5322 (3)
A-319 (2)
AMG 794 (2)
ASP2138 (2)
mosunetuzumab-axgb (2)
NVG-111 (2)
talquetamab-tgvs (2)
teclistamab-cqyv (2)
VIR-5818 (2)
CC-93269 (2)
IMC-F106C (2)
IGM-2323 (2)
AMV564 (2)
CLN-978 (1)
CT-95 (1)
glofitamab-gxbm (1)
GEN1047 (1)
ISB 1342 (1)
MGD024 (1)
odronextamab (1)
SAR443216 (1)
GNC-035 (1)
AMG 701 (1)
MK-4002 (1)
REGN4018 (1)
XmAb14045 (1)
JNJ-63898081 (1)
AMG 509 (1)
A-337 (0)
ABBV-184 (0)
ABBV-383 IV (0)
ADG138 (0)
AFM11 (0)
AMG 211 (0)
AMG 305 (0)
AMG 562 (0)
ASP2074 (0)
AVC-001 (0)
AZD0486 (0)
BA1202 (0)
BC3448 (0)
BI 765049 (0)
BNT142 (0)
BS006 (0)
CBA-1535 (0)
CC-1 (0)
CC-3 (0)
CCW702 (0)
CD30 biAb-AATC (0)
CLN-049 (0)
CM350 (0)
CM355 (0)
CMG1A46 (0)
ERY974 (0)
TRBS07 (0)
F182112 (0)
GB261 (0)
GEM333 (0)
GEN1044 (0)
GEN3017 (0)
GNC-039 (0)
GNR-084 (0)
HBM7004 (0)
HPN536 (0)
IGM-2537 (0)
IGM-2644 (0)
IO-312 (0)
ISB 1302 (0)
ISB 2001 (0)
JNJ-6358 (0)
JNJ-63709178 (0)
JNJ-67571244 (0)
JNJ-8343 (0)
JNJ-8543 (0)
JNJ-8902 (0)
JS203 (0)
LBL-033 (0)
FBTA05 (0)
M701 (0)
M802 (0)
MBS314 (0)
MK-6070 (0)
MP0533 (0)
NG-641 (0)
NGM936 (0)
NILK-2301 (0)
NILK-2501 (0)
NM28-2746 (0)
PF-06671008 (0)
PF-07062119 (0)
PF-07260437 (0)
PIT565 (0)
QLS31904 (0)
QLS31905 (0)
QLS32015 (0)
RG6007 (0)
RG6129 (0)
RG6232 (0)
RG6286 (0)
RG6353 (0)
RG6524 (0)
RGV004 (0)
catumaxomab (0)
SAIL66 (0)
SAR440234 (0)
TAK-186 (0)
TQB2825 (0)
TQB2934 (0)
UMG2-CD3 BTCE (0)
Undisclosed HER2Bi-armed ATC (0)
WVT078 (0)
XmAb968 (0)
Y150 (0)
ZG006 (0)
AMG 160 (0)
activated CIK and bispecific antibody (0)
activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)
ARB202 (0)
RG6160 (0)
RG7802 (0)
AMG 330 (0)
AMG 673 (0)
GNC-038 (0)
AMG 596 (0)
RG6234 (0)
AMG 910 (0)
huCD33-BsAb (0)
REGN5458 (0)
APVO436 (0)
GD2xCD3 (0)
MGD009 (0)
AMG 420 (0)
XmAb13676 (0)
JNJ-8780 (0)
RG6194 (0)
AMG 110 (0)
MCLA-117 (0)
XmAb18087 (0)
AMG 199 (0)
REGN5459 (0)
zolbetuximab-clzb (11)
ZL-1211 (4)
TJ-CD4B (4)
AB011 (2)
TST001 (2)
MIL93 (1)
Q-1802 (1)
ASKB589 (0)
BNT141 (0)
DR30303 (0)
FL-301 (0)
IBI360 (0)
LB4330 (0)
LM-102 (0)
PM1032 (0)
PM3023 (0)
PT886 (0)
SG1906 (0)
TAC101-Claudin18.2 (0)
›
Associations
News
Trials
Filter by
Latest
11ms
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (clinicaltrials.gov)
P1, N=320, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Phase classification: P1a/1b --> P1 | Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
11 months ago
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • IBI-389
12ms
Safety, tolerability and preliminary efficacy of IBI389 in subjects with advanced pancreatic cancer: An open-label phase II study (ChiCTR2300077565 )
P2, N=42, Not yet recruiting, First Affiliated Hospital of Anhui Medical University
12 months ago
New P2 trial • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
gemcitabine • albumin-bound paclitaxel • IBI-389
2years
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (clinicaltrials.gov)
P1a/1b, N=320, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
2 years ago
Enrollment open • Combination therapy • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • IBI-389
almost3years
Safety and Efficacy of IBI389 Single Agent and in Combination With Sintilimab in Patients With Advanced Malignancies (clinicaltrials.gov)
P1a/1b, N=320, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
almost 3 years ago
Clinical • New P1 trial • Combination therapy
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • IBI-389
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login